Archive
1250 articles, sorted by publication time.
A flexible implant can directly measure lactate changes around the heart, brain, and muscles, and signals earlier than a blood pressure decline in a septic shock model; however, the evidence remains limited to animals, while external electronics and transcutaneous wires have yet to be eliminated.
A new spatial transcriptomics platform tracks cancer-cell neoantigens and corresponding T cells within the same tissue section, revealing microenvironments where tumor-specific immune responses cluster. The findings could help advance precision immunotherapy, but the platform currently remains primarily a research tool studied in a limited set of tumor samples.
Bunsen aims to translate research objectives into executable molecular modeling workflows, independently analyze results, and plan the next steps. The system is available for early access to a limited number of customers, but its purported benefits in shortening R&D timelines and increasing candidate drug hit rates are not yet supported by independent data.
The emerging field of bioiontronics goes beyond measuring electrical current to identify and manipulate ions, neurotransmitters, and protein signals. It could connect personalized diagnostics with on-demand treatment, but most applications remain constrained by miniaturization, long-term implantation, and signal interpretation.
Whole-genome data from more than 200 patients with aggressive lymphoma suggest that inherited genetic differences may contribute to CAR-T–related inflammatory toxicity and in vivo expansion; however, some signals were not replicated across trials, and clinical screening remains some way off.
The FDA and CalciMedica have reached agreement on the primary endpoint for the next-stage trial, but the respiratory failure signal supporting this development pathway comes from only a small number of events and still requires validation in a prospective study.
LKB1-deficient lung tumors locally release prostaglandin E2, suppressing appetite through pulmonary sensory nerves; blocking this signal reduces wasting and extends survival in mice, but efficacy in humans has not yet been demonstrated.
Nearly $150 million from the public offering, together with a concurrent equity investment from Sanofi, gives Scribe additional capital to advance its PCSK9-silencing therapy, which does not rewrite the DNA sequence; the real test will be the first human data in 2027.
The three-year restructuring will redirect funding toward more than 20 Phase 3 trials and redraw the company’s UK R&D footprint; this acceleration plan is also a test of whether new products can take over before its leading HIV drug loses exclusivity.
The material first captures growth factors already present in the body, then releases them locally in response to pulling forces from repair cells; early results show faster wound closure, but multiple hurdles remain before it can be used for complex chronic wounds such as diabetic foot wounds.
The research team first used ProteinMPNN to reshape proteins, then subjected them to continuous evolution to select for function; the resulting proteases’ selected specificity for the neurodegeneration-related protein ataxin-2 was more than 79-fold higher than that of the best version evolved from the natural enzyme.
Elsa is now connected to more than 40 application and review data sources and was originally intended to provide deeper support for drug reviews, trials, and inspections. Following a series of personnel changes, the pace of implementation, lines of responsibility, and transparency have become more urgent issues than functionality.